Lon-PDH axis
长PDH轴
基本信息
- 批准号:10652122
- 负责人:
- 金额:$ 4.51万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-04-01 至 2023-03-31
- 项目状态:已结题
- 来源:
- 关键词:AllelesArchitectureAstrocytesAtrophicCatabolismCellsCellular StressCerebrumCitric Acid CycleDietary InterventionDiseaseEnergy MetabolismFailureFatty AcidsFibroblastsFunctional disorderGatekeepingGenesGlucoseGlycolysisGoalsHeart DiseasesHumanImpairmentInvestigationKetone BodiesKnowledgeLeucineLinkMalignant NeoplasmsMediatingMissense MutationMitochondriaMolecularMutationNerve DegenerationNeurologicNeuronsOutcomeParentsPathogenicityPatientsPeptide HydrolasesPharmacologyPositioning AttributeProductionProlinePyruvate Dehydrogenase ComplexRegulationSiblingsSkinStreamTestingVariantbrain cellendopeptidase Lainduced pluripotent stem cellmitochondrial metabolismnoveloxidationparent grantproteostasispyruvate dehydrogenasestem cell differentiationtherapeutic protein
项目摘要
SUMMARY
From the parent grant R01 GM136905-01 entitled, “Mitochondrial metabolism and the Lon-PDH axis”.
The human Lon protease is a master regulator of mitochondrial proteostasis, which is essential for
regulating mitochondrial energy metabolism and mitigating cell stress. We recently identified a novel
pathogenic variant in the LONP1 gene encoding Lon, in two siblings with profound neurologic
impairment, cerebral and cerebellar atrophy, in which proline at position 761 was replaced by leucine
(Lon-P761L). Primary skin fibroblasts from these siblings, showed substantially reduced activity of
pyruvate dehydrogenase (PDH). Our results demonstrated that PDH deficiency was caused by the
failure of Lon-P761L to degrade the phosphorylated E1a subunit of PDH, which accumulates and
inhibits PDH activity. PDH is the central gatekeeper linking glycolysis to the tricarboxylic acid (TCA)
cycle and a key regulatory node for glucose and fatty acid catabolism. Neurons generate ATP almost
exclusively by glucose oxidation, thus fully active PDH is crucial. We hypothesize that wild type Lon
regulates the activity and architecture of the PDH complex and is crucial for calibrating mitochondrial
metabolism and energetics. In this project, we will employ patient- and parent- derived fibroblasts, and
also induced pluripotent stem cells (iPSCs), which have been generated from these fibroblasts. The
patient- and parent- derived iPSCs will be differentiated into neurons and astrocytes. Using these cells,
Aim 1 will test the hypothesis that Lon-mediated degradation regulates the architecture and activity of
the PDH complex. Aim 2 will identify the up- and down- stream modulators of the Lon-PDH axis, which
are altered in cells expressing wild type Lon versus Lon-P761L. In Aim 3, we will investigate the
regulation of PDH by Lon in iPSCs differentiated into neurons and astrocytes. Our investigation will
establish new molecular mechanisms for the Lon-dependent regulation of PDH. The knowledge gained
will also help to identify potential therapeutic protein targets, pharmacologic and dietary interventions
for increasing PDH activity and/or for treating PDH deficiency associated with Lon dysfunction. These
outcomes have a broader impact for understanding how PDH activity and mitochondrial metabolism
can be calibrated in both rare and more common disorders such as heart disease, cancer and
neurodegeneration.
概括
来自父母的授予R01 GM136905-01,标题为“线粒体代谢和LON-PDH轴”。
人类lon蛋白酶是线粒体蛋白质的主要调节剂,这对于
调节线粒体能量代谢和减轻细胞应激。我们最近确定了一本小说
LONP1基因的致病变异,编码LON,在具有深刻神经系统的两个兄弟姐妹中
损伤,大脑和小脑萎缩,其中761位的脯氨酸被亮氨酸取代
(LON-P761L)。这些兄弟姐妹的一级皮肤成纤维细胞,显示出大幅降低的活性
丙酮酸脱氢酶(PDH)。我们的结果表明,PDH缺乏症是由
LON-P761L未能降解PDH的磷酸化E1A亚基,该亚基积聚和
抑制PDH活性。 PDH是将糖酵解与三核酸(TCA)连接的中央守门人
周期和葡萄糖和脂肪酸分解代谢的关键调节节点。神经元几乎产生ATP
仅通过葡萄糖氧化,因此完全活跃的PDH至关重要。我们假设野生型LON
调节PDH复合物的活性和结构,对于校准线粒体至关重要
代谢和能量学。在这个项目中,我们将采用患者和父母衍生的成纤维细胞,以及
还诱导了由这些成纤维细胞产生的多能干细胞(IPSC)。
患者和父母衍生的IPSC将分为神经元和星形胶质细胞。使用这些细胞,
AIM 1将检验以下假设:LON介导的降解调节
PDH复合物。 AIM 2将识别LON-PDH轴的上流和下游调节器,该调制器
在表达野生型LON与LON-P761L的细胞中发生了变化。在AIM 3中,我们将调查
IPSC中LON对PDH的调节分化为神经元和星形胶质细胞。我们的投资意志
为PDH的LON依赖性调节建立新的分子机制。知识获得了
还将有助于确定潜在的治疗蛋白靶标,药物和饮食干预措施
用于增加PDH活性和/或用于治疗与LON功能障碍相关的PDH缺乏。这些
结果对了解PDH活性和线粒体代谢有更广泛的影响
可以在罕见和更常见的疾病中校准,例如心脏病,癌症和
神经变性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CAROLYN K SUZUKI其他文献
CAROLYN K SUZUKI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CAROLYN K SUZUKI', 18)}}的其他基金
Mitochondrial metabolism and the Lon-PDH axis
线粒体代谢和 Lon-PDH 轴
- 批准号:
10594025 - 财政年份:2020
- 资助金额:
$ 4.51万 - 项目类别:
Mitochondrial metabolism and the Lon-PDH axis
线粒体代谢和 Lon-PDH 轴
- 批准号:
10620384 - 财政年份:2020
- 资助金额:
$ 4.51万 - 项目类别:
Mitochondrial metabolism and the Lon-PDH axis
线粒体代谢和 Lon-PDH 轴
- 批准号:
10379257 - 财政年份:2020
- 资助金额:
$ 4.51万 - 项目类别:
Mitochondrial metabolism and the Lon-PDH axis
线粒体代谢和 Lon-PDH 轴
- 批准号:
10728404 - 财政年份:2020
- 资助金额:
$ 4.51万 - 项目类别:
Regulating mtDNA and mtRNA dynamics by the mitochondrial AAA+ Lon protease
通过线粒体 AAA Lon 蛋白酶调节 mtDNA 和 mtRNA 动力学
- 批准号:
9187845 - 财政年份:2015
- 资助金额:
$ 4.51万 - 项目类别:
Mitochondrial chaperones mortalin and Tid1 in protein degradation
蛋白质降解中的线粒体伴侣 mortalin 和 Tid1
- 批准号:
8707617 - 财政年份:2011
- 资助金额:
$ 4.51万 - 项目类别:
Mitochondrial chaperones mortalin and Tid1 in protein degradation
蛋白质降解中的线粒体伴侣 mortalin 和 Tid1
- 批准号:
8192595 - 财政年份:2011
- 资助金额:
$ 4.51万 - 项目类别:
Mitochondrial chaperones mortalin and Tid1 in protein degradation
蛋白质降解中的线粒体伴侣 mortalin 和 Tid1
- 批准号:
8311645 - 财政年份:2011
- 资助金额:
$ 4.51万 - 项目类别:
High throughput screening assays to identify small molecules that target the ClpX
通过高通量筛选分析来识别靶向 ClpX 的小分子
- 批准号:
7994954 - 财政年份:2010
- 资助金额:
$ 4.51万 - 项目类别:
High throughput screens for modulators of mitochondrial ATP-dependent proteolysis
高通量筛选线粒体 ATP 依赖性蛋白水解调节剂
- 批准号:
7914479 - 财政年份:2009
- 资助金额:
$ 4.51万 - 项目类别:
相似国自然基金
“共享建筑学”的时空要素及表达体系研究
- 批准号:
- 批准年份:2019
- 资助金额:63 万元
- 项目类别:面上项目
基于城市空间日常效率的普通建筑更新设计策略研究
- 批准号:51778419
- 批准年份:2017
- 资助金额:61.0 万元
- 项目类别:面上项目
宜居环境的整体建筑学研究
- 批准号:51278108
- 批准年份:2012
- 资助金额:68.0 万元
- 项目类别:面上项目
The formation and evolution of planetary systems in dense star clusters
- 批准号:11043007
- 批准年份:2010
- 资助金额:10.0 万元
- 项目类别:专项基金项目
新型钒氧化物纳米组装结构在智能节能领域的应用
- 批准号:20801051
- 批准年份:2008
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Project 2: Impact of H1/H2 haplotypes on cellular disease-associated phenotypes driven by FTD-causing MAPT mutations
项目 2:H1/H2 单倍型对 FTD 引起的 MAPT 突变驱动的细胞疾病相关表型的影响
- 批准号:
10834336 - 财政年份:2023
- 资助金额:
$ 4.51万 - 项目类别:
UCLA High-Throughput Neuropsychiatric Disorder Phenotyping Center (UCLA HT-NPC)
加州大学洛杉矶分校高通量神经精神疾病表型中心 (UCLA HT-NPC)
- 批准号:
10643541 - 财政年份:2023
- 资助金额:
$ 4.51万 - 项目类别:
Cell Specific Perturbations of the Proteome in Alzheimer's Disease
阿尔茨海默病中蛋白质组的细胞特异性扰动
- 批准号:
10375285 - 财政年份:2021
- 资助金额:
$ 4.51万 - 项目类别:
Project 2: Impact of H1/H2 haplotypes on cellular disease-associated phenotypes driven by FTD-causing MAPT mutations
项目 2:H1/H2 单倍型对 FTD 引起的 MAPT 突变驱动的细胞疾病相关表型的影响
- 批准号:
10295518 - 财政年份:2021
- 资助金额:
$ 4.51万 - 项目类别:
Sex-specific Molecular Profiling to Understand Pathology and Identify Causal Genes and Drug Targets for Alzheimer's Disease
通过性别特异性分子分析来了解阿尔茨海默病的病理学并识别致病基因和药物靶点
- 批准号:
10300830 - 财政年份:2021
- 资助金额:
$ 4.51万 - 项目类别: